EL SEGUNDO, Calif., Nov. 13 /PRNewswire/ -- BioDiscovery announced today that it joined Illumina Connect, a bioinformatics program offered by Illumina, Inc., for downstream analysis of microarray data. After collaborating with Illumina, BioDiscovery has successfully created an interface that allows customers using both Illumina’s BeadStudio software to seamlessly process their data in BioDiscovery’s Nexus CGH advanced copy number analysis software.
Nexus CGH is BioDiscovery’s platform-independent solution for the analysis and visualization of multiple samples for identification of regions of chromosomal gain and loss in a population, and performing statistical association studies. Nexus CGH can easily handle large projects including those with thousands of Illumina high-density arrays.
Omoshile Clement, Ph.D., Illumina’s Senior Product Manager of Platforms said, “Interest in Illumina Connect has continued to grow because bioinformatics software and service providers recognize the value that Illumina technology brings to their customers. Now that BioDiscovery is a partner, we are excited to work with them to make it easier for customers to access the power of Illumina’s genotyping applications for their studies.”
“BioDiscovery’s drive for platform independence has been realized with Nexus CGH, said Dr. Soheil Shams, President of BioDiscovery. “We are delighted to work with Illumina to create an interface between our products, and to create greater value for scientists and the medical community looking to advance their downstream analysis functionality,” said Dr. Shams.
“The user-friendly Nexus interface enables researchers to answer important biological questions without the need for advanced statistical or programming knowledge. With the integration of Illumina’s BeadStudio and Nexus CGH, our customers can go from raw data to biological insight in a matter of minutes,” said Dr. Shams.
About BioDiscovery, Inc.
BioDiscovery is a leader in the development of microarray advanced bioinformatics software and services that enable its customers to revolutionize drug discovery and diagnostics by efficiently managing, integrating, and analyzing data generated using high-throughput microarray technology. Contact us: 310-414-8100 or http://www.biodiscovery.com
sshams@biodiscovery.com
CONTACT: Soheil Shams, President of BioDiscovery, Inc., +1-310-414-8100,
ext. 221, sshams@biodiscovery.com
Web site: http://www.biodiscovery.com/
